PATHOGENETIC BASES FOR THE DEVELOPMENT OF AN ACUTE PHASE RESPONSE TO INTRAVENOUS ADMINISTRATION OF NITROGEN-CONTAINING BISPHOSPHONATES
- Authors: YAKUSHEVSKAYA O.V1, YURENEVA S.V1
-
Affiliations:
- Acad. V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia
- Issue: No 11 (2013)
- Pages: 19-23
- Section: Articles
- URL: https://journals.eco-vector.com/0300-9092/article/view/247064
- ID: 247064
Cite item
Open Access
Access granted
Abstract
Osteoporosis is a systemic skeletal disease characterized by reduced bone mass and microarchitectural impairment of bone tissue, which result in increased bone fragility. Drugs of varying antiresorptive potency from a class of bisphosphonates have been designed today. The need for the long-term (3-5-year) and regulatory use of the drugs to ensure the adequate efficiency of therapy is associated with its low compliance. Intravenous bisphosphonate formulations (ibandronate, zoledronic acid) that can reduce the frequency of use to once 3-12 months have been designed to enhance therapy compliance. Adverse events (the symptoms of an acute phase response) occurring after intravenous administration of antiresorptive drugs promotes any patient alertness and unwillingness to further use bisphosphonates. Recent international studies have provided a more insight into the pleiotropic mechanism of bisphosphonates and disclosed pathogenetic mechanisms for the development of the symptoms of an acute phase response to these drugs in the treatment of osteoporosis.
Full Text
About the authors
O. V YAKUSHEVSKAYA
Acad. V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia
Email: ykushox83@mail.ru
S. V YURENEVA
Acad. V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia
Email: syureneva@gmail.com
References
- Лесняк О.М., Беневоленская Л.И. Клинические рекомендации «Остеопороз. Диагностика, профилактика и лечение». М.: ГЭОТАР-Медиа; 2009.
- Institute for Clinical Systems Improvement (ICSI). Health care guideline for pacients and families. July, 2006.
- Green A.D., Colon-Emeric C.S., Bastian L., Drake M.T., Lyles K.W. Does this woman have osteoporosis? JAMA. 2004; 292(23): 2890-900.
- Hodgson S.F., Watts N.B., Bilezikian J.P., Clarke B.L., Gray T.K., Harris D.W. et al.; AACE Osteoporosis Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr. Pract. 2003; 9(6): 544-64.
- Black D.M., Boonen S., Cauley J., Delmas P., Eastell R., Reid I. et al. Effect of once-yearly infusion of zoledronic acid 5 mg on spine and hip fracture reduction in postmenopausal women with osteoporosis: The HORIZON Pivotal Fracture Trial. In: 2006 Abstracts: 28th Annual meeting of the American society for bone and mineral research. Philadelphia, September 15-19, 2006; J. Bone Miner. Res. 2006; 21(Suppl.1): abstr. 1054.
- Brown J.P., Josse R.G.; Scientific Advisory Council of the Osteoporosis Society of Canada. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. Can. Med. Assoc. J. 2002; 167(10, Suppl.): S1-34.
- Scottish Intercollegiate Guidelines Network (SIGN) N71: Management of osteoporosis: a national clinical guideline. June, 2003. http://www.sign.ac.uk.
- Lyles K.W., Colon-Emeric C.S., Magaziner J.S., Adachi J.D., Pieper C.F, Mautalen C. et al.; for the HORIZON Recurrent Fracture Trial. Zoledronic acid in reducing clinical fracture and mortality after hip fracture. N. Engl. J. Med. 2007; 357: nihpa40967.
- Manolagas S.C. Birth and death of bone cell: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr.Rev. 2000; 21(2): 115-37.
- Schweitzer D.H., Oostendorp-van de Ruit M., Van der Pluijm G., Lowik C.W, Papapoulos S.E. Interleukin-6 and the acute phase response during treatment of patient with Paget’s disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate. J. Bone Miner. Res. 1995; 10(6): 956-62.
- Olson K., Van Poznak C. Significance and impact of bisphosphonate-induced acute phase responses. J. Oncol. Pharm. Pract. 2007; 13(4): 223-9.
- Kunzmann V., Bauer E., Feurle J., Weissinger F, Tony H.P., Wilhelm M. Stimulation of gammadelta T cells by aminobisphosphotates and induction of antiplasma cell activity in multiple myeloma. Blood. 2000; 96(2): 384-92.
- Bijvoet O.L., Frijlink W.B., Jie K., van der Linden H., Meijer C.J., Mulder H. et al. Role of the mononuclear phagocyte system? Arthr. Rheum. 1980; 23(10): 1193-204.
- Thompson К., Rogers M.J., Coxon F.P., Crockett J.C. Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis. Mol. Pharmacol. 2005; 69(5): 1624-32.
- Thompson K., Rogers M.J. Statins prevent bisphosphonate-induced γ,δ-T-cell proliferation and activation in vitro. J. Bone Miner. Res. 2004; 19(2): 278-88.
- Sauty A., Pecherstorfer M., Zimmer-Roth I., Fioroni P., Juillerat L., Markert M. et al. IL-6 and TNF-й levels after bisphosphonate treatment in vitro and in patient with malignancy. Bone. 1996; 18(6): 133-9.
- Thiebaud D., Sauty A., Burckhardt P., Leuenberger P., Sitzler L., Green J.R. et al. An in vitro and in vivo study of cytokines in the acute phase response associated with bisphosphonates. Calcif. Tissue Int. 1997; 61(5): 386-92.
- Dunford J.E. Molecular targets of the nitrogen containing bisphosphonates: the molecular pharmacology of prenyl synthase inhibition. Curr. Pharm. Des. 2010; 16(27): 2961-9.
- Munns C.F., Rajab M.H., Hong J., Briody J., Hogler W., McQuade M. et al. Acute phase response and mineral status following low dose intravenous zoledronic acid in children. Bone. 2007; 41(3): 366-70.
- Recker R.R., Delmas P.D., Halse J., Reid I.R., Boonen S., Garcia-Hernandez P.A. et al. Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J. Bone Miner. Res. 2008; 23(1): 6-16.
- Bertoldo F., Pancheri S., Zenari S., Boldini S., Giovanazzi B., Zanatta M. et al. Serum 25-Hydroxyvitamin D levels modulate the acute-phase response associated with the first nitrogen-containing bisphosphonate infusion. J. Bone Miner. Res. 2010; 25(3): 447-54.
Supplementary files
